Latest News and Press Releases
Want to stay updated on the latest news?
-
12 June 2026 Announcement no. 8 Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs Pharma Equity Group A/S ("PEG" or...
-
12. juni 2026 Meddelelse nr. 8 Pharma Equity Group vinder international voldgiftssag og tilkendes EUR 10,5 mio. med tillæg af renter og omkostninger Pharma Equity Group A/S ("PEG" eller "Selskabet")...
-
Pharma Equity Group’s subsidiary Reponex takes key step forward in Inflammatory Bowel Disease with upcoming European patent grant May 11, 2026Announcement no. 7 Pharma Equity Group A/S today...
-
Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse 11. maj 2026Meddelelse nr. 7 Pharma Equity Group...
-
The Board of Directors' resolution on the issuance of convertible loans April 28, 2026Announcement no. 6 The Board of Directors of Pharma Equity Group has decided to issue convertible loans in...
-
Bestyrelsens beslutning om udstedelse af konvertible lån 28. april 2026Meddelelse nr. 6 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible obligationer i henhold...
-
Proceedings of the Annual General Meeting of Pharma Equity Group A/S 17 April 2026Company Announcement no. 5 Pharma Equity Group A/S held its annual general meeting on 16 April 2026 at 3:30 pm CEST...
-
Forløb af generalforsamlingen i Pharma Equity Group A/S 17. april 2026Selskabsmeddelelse nr. 5 Den 16. april 2026 kl. 15.30 blev der afholdt ordinær generalforsamling i Pharma Equity Group A/S,...
-
25 March 2026 Announcement no. 4 Notice convening the annual general meeting in Pharma Equity Group A/S The board of directors hereby convenes the annual general meeting in Pharma Equity Group A/S...
-
25. marts 2026 Meddelelse nr. 4 Indkaldelse til ordinær generalforsamling i Pharma Equity Group A/S Bestyrelsen indkalder hermed til den ordinære generalforsamling i Pharma Equity Group A/S (“PEG”...